ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - טבליה - erythromycin as stearate 500 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophylaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - טבליה - erythromycin as stearate 250 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophlaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - erythromycin as stearate - טבליה - erythromycin as stearate 250 mg - erythromycin - erythromycin - treatment of the following infections when caused by susceptible organisms: upper and lower respiratory tract infections. skin and soft tissue infections. conjunctivitis of the newborn caused by chlamydia trachomatis. urogenital infections caused by chlamydia trachomatis. venereal diseases (as an alternative regimen to penicillins and tetracyclines). intestinal amebiasis. legionnaires' disease. long-term prophylaxis in rheumatic fever. short-term prophlaxis against bacterial endocarditis in patients hypersensitive to penicillin who have congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures and surgical procedures of the upper respiratory tract. enteric infections caused by campylobacter jejuni.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

ישראל - עברית - Ministry of Health

a. lapidot pharmaceuticals, ltd - mifepristone - טבליה - mifepristone 200 mg - mifepristone - mifepristone - medical alternative to uterine suction for termination of intra-utrerine pregnancy: - up to and no later than 49 days of amenorrhea (seven weeks) - in sequential use with a prostaglandin analogue misoprostol 400 mcg per os administered 36 to 48 hours after mifegyne intake. under these conditions the association of mifepristone and prostaglandins leads to a success rate of about 95 per cent of the cases. preparation for the action of prostaglandin analogues in the termination of pregnancy for medical reason (beyond the first trimester). softening and dilatation of the cervix uteri prior to surgical termination of pregnancy during the first trimester.

ישראל - עברית - Ministry of Health

novartis pharma services ag - calcitonin salmon 2200 iu/ml - solution - calcitonin (salmon synthetic) - bone pain associated with osteolysis due to malignancies. paget's disease of bone only in patients who do not respond to alternative treatments or for whom such treatments are not suitable. neurodystrophic disorders.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - rifabutin - קפסולות - rifabutin 150 mg - rifabutin - rifabutin - for the treatment of chronic tuberculosis where there is evidence of acid fast bacteria resistant to rifampicin or to two other alternative drugs. for the treatment of infections caused by mac or other atypical mycobacteria where there is evidence of resistant bacteria as above. for the treatment of infections caused by mac or other atypical mycobacteria in aids patients in all cases not subject to the above restrictions. for prevention of mac infections in aids patients whose cd4 counts lower or eqval to 200/mm3

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 4.5 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - interferon alfa 2a 6 miu / 0.5 ml - solution for injection - interferon alfa-2a - roferon-a is indicated for the treatment of:- condylomata acuminata - hairy cell leukaemia.- aids patients with progressive, asymptomatic kaposi's sarcoma who have a cd4 count > 250/mm3.- chronic phase philadelphia-chromosome positive chronic myelogenous leukaemia. roferon-a is not an alternative treatment for cml patients who have an hla-identical relative and for whom allogeneic bone marrow transplantation is planned or possible in the immediate future. it is still unknown whether roferon-a can be considered as a treatment with a curative potential in this indication.- adult patients with histologically proven chronic hepatitis b who have markers for viral replication, i.e., those who are positive for hbv dna or hbeag.- adult patients with histologically proven chronic hepatitis c who are positive for hcv antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation.- follicular non-hodgkin’s lymphoma.- advanced renal cell carcinoma.- patients with ajcc stage ii m